Refine by
Bioprinting Process Articles & Analysis
17 news found
At the time of her resignation, a recruitment process was initiated which concluded in the appointment of Stefan Blomsterberg. ...
ByCELLINK
CELLINK, a global leader in bioprinting technologies, is proud to announce a pioneering innovation in the field of regenerative medicine and tissue engineering with the launch of CELLINK Vivoink, the first-ever medical-grade bioink specially designed to support researchers on their clinical translational journey. CELLINK Vivoink is optimized for superior printability, mechanical stability, and ...
ByCELLINK
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...
ByCELLINK
Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for the biofabrication of 3D bioprinted tumor models based on cancer cell lines that improve accuracy and rapidly speed up drug development processes, driving down development costs and enabling an improved output. ...
ByCELLINK
Adding Allegro 3D to the portfolio enables BICO Bioprinting to strengthen its position as the global leader in providing 3D bioprinters. ...
Prellis Biologics, Inc. (Prellis), a Bay Area biotherapeutics company, announced today that it has entered into a collaboration and license option agreement with Sanofi S.A. focused on the discovery of antibodies with Prellis’ first-in-class external human immune system (EXIS). The collaboration leverages Prellis’ ability to engineer fully-human lymph node organoids (LNOs™) and ...
Vancouver, BC, Canada - November 30, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, is pleased to announce a research agreement with the University Health Network (UHN). Through this collaboration, Aspect Biosystems will combine its bioprinting technology with UHN’s protocols for differentiating stem ...
However, the current manufacturing methods of biological tissues are not satisfactory enough to be adopted by the medical community. Manufacturing processes need to be standardized and treatments made affordable. Although various bioprinting technology platforms have been developed in recent years to meet these challenges, none of them has proved compatible with ...
ByPoietis
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D ...
BIOLIFE4D’s own innovative 3D bioprinting process provides the ability to reprogram a patient’s own (white) blood cells to iPS cells, and then to differentiate those iPS cells into different types of cardiac cells needed to 3D bioprint individual cardiac components and ultimately a human heart viable for transplant. This means ...
Poietis, 4D Bioprinting company, announces formation of Scientific Advisory Board (SAB) and appointment of two first prominent Scientists in Regenerative Medicine. The SAB will serve as a key strategic resource to Poietis as the company expands capabilities of Next- Generation Bioprinting (NGB) platform to therapeutic applications and develops first implantable tissues such as a ...
ByPoietis
Poietis, leading bioprinting company, and the « Assistance Publique – Hôpitaux de Marseille » (AP-HM) announced today that they have entered into a partnership through the signature the 20th of January of a clinical research collaboration contract on a bioprinted tissue engineering product. The objective of this agreement is to carry out within two years a Phase I clinical ...
ByPoietis
Further, it has developed a novel and unique bioprinting algorithm, consisting of printing parameters optimized for the whole heart. Coupling its proprietary bioink with patient-derived cardiomyocytes and its enabling bioprinting technology, BIOLIFE4D is able to bioprint a heart that, while smaller in size, replicates many of the features of a ...
Poietis, 4D Bioprinting company, announces the issuance by the European Patent Office of a third patent covering its bioprinting technology: Patent No. EP3233499 entitled «Laser printing method and device for implementing said method», which covers in particular the process of bioprinting upwards, previously ...
ByPoietis
The products are based on the Company’s proprietary technology platforms, comprising: GMPrint™, ColVivo™, and novel cell expansion techniques. 3DBio’s GMPrint™ technology is a purpose-built therapeutic-grade 3D-bioprinter, designed and manufactured by 3DBio. GMPrint™ is the first bioprinter purpose-built for therapeutic-grade ...
Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, have announced a scientific partnership to use Poietis’s 4D bioprinting technology for the development and production of liver tissues. This partnership seeks to improve the detection of drug-induced liver lesions as early as the preclinical trial phase. ...
ByPoietis
Poietis, leading bioprinting company and Prometheus, Division of Skeletal Tissue Engineering at KU Leuven, entered into a 2-years Collaborative Research Agreement focused on high-precision 3D Bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration. ...
ByPoietis